# Vardenafil Inhaled for Pulmonary Arterial Hypertension PRN Phase 2B Study

> **NCT04266197** · PHASE2 · COMPLETED · sponsor: **Respira Therapeutics, Inc.** · enrollment: 42 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **COMBINATION_PRODUCT:** Drug: RT234 - vardenafil inhalation powder; Device: Axially Oscillating Sphere dry powder inhaler (AOS DPI)

## Key facts

- **NCT ID:** NCT04266197
- **Lead sponsor:** Respira Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-25
- **Primary completion:** 2024-11-20
- **Final completion:** 2025-01-07
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2025-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04266197

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04266197, "Vardenafil Inhaled for Pulmonary Arterial Hypertension PRN Phase 2B Study". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04266197. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*